Skip to Main Content

Paper Details

Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma.
Clin Cancer Res
4
2022
Breast Cancer, CRISPR, ER, Glioblastoma, IRE1, PTX, Paclitaxel, SSR3, SSR3 protein, Translocon-associated Protein Subunit SSR3, breast and pancreatic cancer, breast cancer, breast cancer cells, endoplasmic reticulum (ER) protein SSR3, genes, glioblastomas, glioma, glioma cells, gliomas, human, human glioma cells, patient, patients, taxane
Author NameAffiliation
Craig HorbinskiNorthwestern University Feinberg School of Medicine
Patrick D HsuInnovative Genomics Institute, University of California berkeley
Patrick D HsuUniversity of California berkeley
Patrick D HsuCenter for Computational Biology, University of California berkeley
Roger StuppNorthwestern Medicine Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
Roger StuppFeinberg School of Medicine, Northwestern University
Adam M SonabendNorthwestern Medicine Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
  • 1 - 7

Datasets

Release 1.2